PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
22.06%
Revenue growth of 22.06% vs. zero growth in Drug Manufacturers - Specialty & Generic. Walter Schloss might still want to see if it can translate into profits.
127.38%
Gross profit growth of 127.38% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a slight advantage that could be built upon.
38.32%
Positive EBIT growth while Drug Manufacturers - Specialty & Generic median is negative. Peter Lynch might see a strong competitive advantage in operations.
38.32%
Positive operating income growth while Drug Manufacturers - Specialty & Generic is negative. Peter Lynch would spot a big relative advantage here.
65.75%
Positive net income growth while Drug Manufacturers - Specialty & Generic median is negative. Peter Lynch would view this as a notable competitive advantage.
66.67%
Positive EPS growth while Drug Manufacturers - Specialty & Generic median is negative. Peter Lynch might see a strong advantage in per-share earnings compared to peers.
66.67%
Diluted EPS growth of 66.67% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a slight edge that could improve over time.
5.20%
Share change of 5.20% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss would see if the modest difference matters long-term.
5.20%
Diluted share change of 5.20% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a slight difference in equity issuance policy.
No Data
No Data available this quarter, please select a different quarter.
293.60%
OCF growth of 293.60% while Drug Manufacturers - Specialty & Generic is zero. Walter Schloss might see a modest positive difference, which can compound over time.
184.22%
FCF growth of 184.22% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a slight edge that could compound over time.
No Data
No Data available this quarter, please select a different quarter.
-34.22%
Negative 5Y CAGR while Drug Manufacturers - Specialty & Generic median is 5.84%. Seth Klarman would see if others are at least growing moderately, indicating a firm-specific problem.
-9.09%
Negative 3Y CAGR while Drug Manufacturers - Specialty & Generic median is 2.58%. Seth Klarman would examine if the sector is otherwise stable, indicating a company-specific issue.
2504.48%
OCF/share CAGR of 2504.48% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a modest edge that can add up if momentum improves.
162.10%
OCF/share CAGR of 162.10% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a slight advantage that can compound if momentum builds.
185.89%
3Y OCF/share growth > 1.5x Drug Manufacturers - Specialty & Generic median of 13.53%. Joel Greenblatt might see a recent competitive advantage translating into cash improvements.
-113.65%
Negative 10Y net income/share CAGR vs. Drug Manufacturers - Specialty & Generic median of 33.04%. Seth Klarman might see a fundamental problem if peers maintain growth.
-168.21%
Negative 5Y CAGR while Drug Manufacturers - Specialty & Generic median is 27.72%. Seth Klarman might see a specific weakness if peers maintain profitable expansions.
-153.14%
Negative 3Y CAGR while Drug Manufacturers - Specialty & Generic median is 31.03%. Seth Klarman might see a pressing concern if the rest of the sector is stable or growing.
9548.01%
Equity/share CAGR exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 21.18% over 10 years. Joel Greenblatt would see if a high ROE underlies this compounding advantage.
-27.53%
Negative 5Y equity/share growth while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman suspects firm-specific weaknesses if peers grow equity mid-term.
-56.57%
Negative 3Y equity/share growth while Drug Manufacturers - Specialty & Generic median is -13.89%. Seth Klarman sees a short-term weakness if peers still expand net worth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
13.57%
AR growth of 13.57% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss checks if the difference points to new credit strategy or stronger sales push.
3.26%
Inventory growth of 3.26% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss checks if we’re preparing for a sales push or risking overstock.
2.91%
Asset growth of 2.91% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss sees a slight advantage if expansions yield good returns on capital.
-2.10%
Negative BV/share change while Drug Manufacturers - Specialty & Generic median is -0.20%. Seth Klarman sees a firm-specific weakness if peers accumulate net worth.
-19.58%
Debt is shrinking while Drug Manufacturers - Specialty & Generic median is rising. Seth Klarman might see an advantage if growth remains possible.
271.70%
R&D growth of 271.70% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss wonders if a slight increase yields a meaningful competitive edge.
36.61%
SG&A growth far above Drug Manufacturers - Specialty & Generic median. Jim Chanos sees potential red flags in cost management or diminishing returns on spending.